Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers with HIV
This study is not yet open for patient recruitment.
Sponsored by: | National Institute of Allergy and Infectious Diseases (NIAID) Secure the Future Foundation
|
---|---|
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
Purpose
HIV infected women in South Africa have a high risk of tuberculosis (TB) infection. Children born to HIV infected mothers may be more likely to be exposed to and become infected with TB, and children infected with TB have a higher risk of developing severe disease than adults with TB. The purpose of this study is to determine if the antibiotic isoniazid (INH) will prevent TB infection in infants born to HIV infected mothers in South Africa.
Condition | Treatment or Intervention | Phase |
---|---|---|
HIV Infections Tuberculosis Pneumocystis carinii Pneumonia |
Drug: Isoniazid Drug: Sulfamethoxazole-Trimethoprim |
Phase II Phase III |
MedlinePlus related topics: AIDS; Fungal Infections; Pneumocystis Carinii Infections; Pneumonia; Respiratory Diseases; Tuberculosis
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (INH) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among South Africans with Perinatal Exposure to HIV
Expected Total Enrollment: 1300
TB and HIV are major public health problems in South Africa, and the incidence of TB in South Africa is among the highest in the world. TB is caused by the highly contagious bacterium Mycobacterium tuberculosis. The use of INH prophylaxis in adults has been associated with reduced risk of TB disease in high-risk populations. Delay in initiating INH prophylaxis in children has resulted in more cases of childhood TB infection. This study will evaluate the effectiveness of INH prophylaxis in preventing TB infection in South African infants born to HIV infected mothers.
Infants will be randomly assigned to receive either INH or placebo by mouth daily, beginning between the 91st and 120th day of life, and at least 90 days after Bacille Calmette-Guerin (BCG) vaccination. HIV infected infants will receive daily sulfamethoxazole-trimethoprim (SMX/TMP) as Pneumocystic carinii pneumonia (PCP) prophylaxis until at least 1 year of age; HIV uninfected infants will receive SMX/TMP until at least 6 months of age.
This study will last 192 weeks. Study visits will occur at study entry and every 12 weeks until Week 192. A physical exam and blood collection will occur at each study visit. Infants will be assessed for peripheral neuropathy every 12 weeks until Week 96 and for TB at Weeks 96, 144, and 192. The study will also assess medication adherence.
Eligibility
Ages Eligible for Study: 91 Days - 120 Days, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location Information
More Information
Click here for more information about isoniazid
Click here for more information about sulfamethoxazole-trimethoprim
Haga clic aquí para ver información sobre este ensayo clínico en español.
Publications
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |